Alzheimer’s Therapeutic Market Size And Forecast
Alzheimer’s Therapeutic Market size was valued at USD 3.76 Billion in 2021 and is projected to reach USD 12.8 Billion by 2030, growing at a CAGR of 12.1% from 2022 to 2030.
The increasing prevalence of Alzheimer’s disease, rising health awareness among people about the same, and the introduction of novel technologies and drugs to improve life expectancy are driving the growth of the Global Alzheimer’s Therapeutic market significantly. The Global Alzheimer’s Therapeutic Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
>>> Get | Download Sample Report @ –
Global Alzheimer’s Therapeutic Market Definition
Imagine Alzheimer's disease as a thief, slowly stealing away your mind. It usually shows up around middle age and is a major cause of what we call dementia – that's when your thinking skills and brainpower fade so much it messes with your everyday life. And sadly, it only gets worse over time. Alzheimer's is truly heartbreaking, with symptoms piling up as time goes on. At first, you might just notice some mild memory problems, but as Alzheimer's progresses, people can lose the ability to even have a simple conversation or understand what's happening to them. Memory loss is a big one, but there's also repetitive movements, trouble sleeping (insomnia), feeling anxious or depressed, getting agitated easily, and losing the ability to think clearly – these are just some of the signs and symptoms of this cruel disease.
Alzheimer's meds might not stop the disease in its tracks, but they can make life a little easier by easing dementia's effects and boosting happiness for those living with it. It's more common to develop Alzheimer's after 65, and the numbers are honestly staggering – it's estimated someone new gets diagnosed with AD all the time, adding to the almost 35 million people worldwide already affected. The good news? We're getting way better at diagnosing and treating Alzheimer's and other brain diseases. Even though clinical diagnoses are wrong 10-15% of the time, we're using special biomarkers to get things right more often.
Global Alzheimer’s Therapeutic Market Overview
Okay, so the market overview in this report really digs into the nuts and bolts of what's moving things – think drivers pushing the market forward, the restraints holding it back, the exciting opportunities on the horizon, and the tough challenges the industry's up against. This Global Alzheimer’s Therapeutic Market report also gives you our best guess on how the market's revenue will grow over time. We're predicting some pretty amazing growth for the Global Alzheimer’s Therapeutic Market because there's a growing need for gentler treatments for Alzheimer's. Plus, more people are getting Alzheimer's, we're all getting smarter about health, and new tech and meds are helping people live longer, which is really giving the market a boost.
Additionally, technological advancements for the development of innovative drugs and techniques in the treatment of Alzheimer’s disease and increasing investment in R&D activities are also promoting the market growth. Furthermore, the rise in the geriatric population across the globe, growth in the healthcare sector, and increasing government initiatives and support in the form of funds and grants to improve diagnostic techniques and treatment procedures, also boost the growth of the Alzheimer’s Therapeutic market.
Moreover, an increase in the patient population of Alzheimer’s disease, increased product development, and launch activities and growth potential in developing nations is expected to provide profitable growth opportunities to the market players in the Global Alzheimer’s Therapeutic market during the forecast period. However, late-stage drug failures, a lack of surrogate markers for drug discovery and drug development, insufficient research funding, and lengthy uncertain processes are expected to hinder the growth of the Global Alzheimer’s Therapeutic Market over the forecast period.
Global Alzheimer’s Therapeutic Market Segmentation Analysis
The Global Alzheimer’s Therapeutic Market is segmented on the basis of Product Type, Distribution Channel, and Geography.
Alzheimer’s Therapeutic Market, Product Type
• Cholinesterase inhibitors• N-Methyl-D-Aspartate (NMDA) receptor antagonist• Biomarkers• Others
Based on Product Type, the market is segmented into Cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, Biomarkers, and Others. the cholinesterase inhibitors segment accounts for the highest revenue share of the Global Alzheimer’s Therapeutics Market in 2020 and is expected to dominate the market over the forecast period as they are commonly used to treat symptoms associated with memory, thinking, language, judgment, and other thought processes by healthcare professionals. This is driving the market
Alzheimer’s Therapeutic Market, By Distribution Channel
• Hospital Pharmacy• Retail Pharmacy• Online Pharmacy
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy on the basis of Distribution Channel. Due to the increasing use of online pharmacy apps or websites from the comfort of home among customers, especially during the COVID-19 pandemic due to sudden lockdown and quarantine restrictions, the online pharmacy segment is expected to hold the largest revenue share of the Global Alzheimer’s Therapeutic market during the forecast period. This has further fueled the market growth of this segment.
Alzheimer’s Therapeutic Market, By Geography
• North America• Europe• Asia Pacific• Rest of the World
On the basis of Geography, the Global Alzheimer’s Therapeutic Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Among the regional markets, North America accounts for the largest revenue share in Global Alzheimer’s Therapeutic Market in 2020 and is expected to retain its dominance throughout the forecast period. The revenue growth in the North American market is mainly attributed to the increased investment in R&D activities for the development of technologically advanced techniques and innovative drugs in the treatment of Alzheimer’s disease.
Additionally, the increasing geriatric population, rising incidence, and prevalence of Alzheimer’s disease, rising healthcare sectors, presence of skilled professionals, and wide availability of technologically advanced Alzheimer’s Therapeutic are the major factors that boost the Alzheimer’s Therapeutic market in the region. The market in the Asia Pacific is projected to witness expansion at a significant growth rate during the forecast period, owing to the increasing focus on the development of healthcare infrastructure and rising prevalence of Alzheimer’s disease in the developing nations such as China, and India in this region.
Key Players
The “Global Alzheimer’s Therapeutic Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H. Lundbeck A/S, AC Immune, TauRx Pharmaceuticals Ltd., Actavis plc., Forest Laboratories, Teva Pharmaceuticals Industries Ltd., Janssen Pharmaceutical, GE Healthcare, Eli Lilly and Company, DiaGenic ASA, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca, and Daiichi Sankyo Company Ltd., and among others. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Key Developments
• In November 2021, Brigham and Women’s Hospital in Boston, USA began a clinical trial to test the safety and efficacy of a new nasal vaccine for Alzheimer’s disease.
• In October 2021, Salk Institute started a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 to check its safety in humans.
• In August 2019, Oxford Brain Diagnostics (an Oxford University spinoff) was founded to provide a new method for diagnosing Alzheimer’s disease from MRI scans.
Report Scope
| REPORT ATTRIBUTES | DETAILS |
|---|
| Study Period | 2018-2030 |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Historical Period | 2018-2020 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Pfizer, Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H. Lundbeck A/S, AC Immune, TauRx Pharmaceuticals Ltd. |
| Segments Covered | • By Product Type
• By Distribution Channel
• By Geography |
| Customization Scope | Free report customization (equivalent to up to 4 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope |
Top Trending Reports
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .
Reasons to Purchase this Report
We'll dive deep into the market, looking at both the money side and the human side with qualitative and quantitative analysis, breaking it down by different groups. You'll get the actual market value – think USD in billions – for each of these groups and subgroups. We'll also point out which region and segment we think will be the fastest growing and which will be the biggest overall. Expect a geography-based analysis, showing you where the product/service is being used most and what's driving the market in each place. Plus, a competitive landscape section ranking the top players, covering new product releases, partnerships, expansions, and acquisitions from the last five years. You'll also get detailed company profiles, including an overview, key insights, product comparisons, and even a SWOT analysis for the big players. We'll give you a current and future market outlook, highlighting recent developments, growth opportunities, what's helping and hindering growth in both new and established areas. We'll also dig into the market from all angles using Porter's five forces analysis and explain the market through the value chain. Finally, expect a rundown of market dynamics, growth opportunities, and 6-month post-sales analyst support to help you get the most out of the information.
Customization of the Report
• In case of any please connect with our sales team, who will ensure that your requirements are met.
